Sun finally shines on Horizant, as FDA OK’s GSK-XenoPort RLS drug
This article was originally published in Scrip
Executive Summary
Investors jumped for joy on 7 April on the news that GlaxoSmithKline and its partner XenoPort finally gained the US FDA's blessing for their extended-release gabapentin enacarbil product Horizant (XP13512/GSK1838262) as a treatment for adults with moderate-to-severe primary restless legs syndrome (RLS) – an approval that came after a long and winding road.
You may also be interested in...
Arbor's Bid For XenoPort Likely Driven By Effort To Grow Horizant
With minimal unencumbered pipeline assets to offer, XenoPort's value to Arbor apparently lies in positive sales trends for the modest-selling restless legs and postherpetic neuralgia drug.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.